Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial

Detalles Bibliográficos
Autores principales: Williams, WB, Jones, K, Krambrink, A, Grove, D, Liu, P, Yates, NL, Moody, MA, Ferrari, G, Pollara, J, Moodie, Z, Morgan, CA, Liao, H, Montefiori, DC, Ochsenbauer, C, Kappes, J, Hammer, S, Mascola, J, Koup, R, Corey, L, Nabel, G, Gilbert, P, Churchyard, G, Keefer, M, Graham, BS, Haynes, BF, Tomaras, GD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441791/
http://dx.doi.org/10.1186/1742-4690-9-S2-O55
_version_ 1782243376976887808
author Williams, WB
Jones, K
Krambrink, A
Grove, D
Liu, P
Yates, NL
Moody, MA
Ferrari, G
Pollara, J
Moodie, Z
Morgan, CA
Liao, H
Montefiori, DC
Ochsenbauer, C
Kappes, J
Hammer, S
Mascola, J
Koup, R
Corey, L
Nabel, G
Gilbert, P
Churchyard, G
Keefer, M
Graham, BS
Haynes, BF
Tomaras, GD
author_facet Williams, WB
Jones, K
Krambrink, A
Grove, D
Liu, P
Yates, NL
Moody, MA
Ferrari, G
Pollara, J
Moodie, Z
Morgan, CA
Liao, H
Montefiori, DC
Ochsenbauer, C
Kappes, J
Hammer, S
Mascola, J
Koup, R
Corey, L
Nabel, G
Gilbert, P
Churchyard, G
Keefer, M
Graham, BS
Haynes, BF
Tomaras, GD
author_sort Williams, WB
collection PubMed
description
format Online
Article
Text
id pubmed-3441791
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34417912012-09-18 Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial Williams, WB Jones, K Krambrink, A Grove, D Liu, P Yates, NL Moody, MA Ferrari, G Pollara, J Moodie, Z Morgan, CA Liao, H Montefiori, DC Ochsenbauer, C Kappes, J Hammer, S Mascola, J Koup, R Corey, L Nabel, G Gilbert, P Churchyard, G Keefer, M Graham, BS Haynes, BF Tomaras, GD Retrovirology Oral Presentation BioMed Central 2012-09-13 /pmc/articles/PMC3441791/ http://dx.doi.org/10.1186/1742-4690-9-S2-O55 Text en Copyright ©2012 Williams et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oral Presentation
Williams, WB
Jones, K
Krambrink, A
Grove, D
Liu, P
Yates, NL
Moody, MA
Ferrari, G
Pollara, J
Moodie, Z
Morgan, CA
Liao, H
Montefiori, DC
Ochsenbauer, C
Kappes, J
Hammer, S
Mascola, J
Koup, R
Corey, L
Nabel, G
Gilbert, P
Churchyard, G
Keefer, M
Graham, BS
Haynes, BF
Tomaras, GD
Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
title Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
title_full Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
title_fullStr Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
title_full_unstemmed Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
title_short Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
title_sort multiple antibody specificities (gp41, v1v2, and v3) elicited in the phase ii multiclade (a, b, c) hiv-1 dna prime, rad5 boost vaccine trial
topic Oral Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441791/
http://dx.doi.org/10.1186/1742-4690-9-S2-O55
work_keys_str_mv AT williamswb multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT jonesk multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT krambrinka multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT groved multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT liup multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT yatesnl multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT moodyma multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT ferrarig multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT pollaraj multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT moodiez multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT morganca multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT liaoh multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT montefioridc multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT ochsenbauerc multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT kappesj multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT hammers multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT mascolaj multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT koupr multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT coreyl multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT nabelg multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT gilbertp multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT churchyardg multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT keeferm multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT grahambs multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT haynesbf multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial
AT tomarasgd multipleantibodyspecificitiesgp41v1v2andv3elicitedinthephaseiimulticladeabchiv1dnaprimerad5boostvaccinetrial

Ejemplares similares